Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06558279 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
A Phase 3 study of Myasthenia Gravis, Ocular, sponsored by argenx.
- Active
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT06558279 is a Phase 3 study of Myasthenia Gravis, Ocular that is active but no longer recruiting, run by argenx. The registered enrollment target is 141 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06558279, a Phase 3 study of Myasthenia Gravis, Ocular, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 weeks.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Efgartigimod PH20 SC
- OTHER Placebo PH20 SC
Study Locations (20)
Florida
- Neurology Offices of South Florida - Boca Raton
- SFM Clinical Research, LLC - Boca Raton
- Neurology Associates PA - Maitland
- University of South Florida - Tampa
California
- Loma Linda University Health - Loma Linda
- USC Roski Eye Institute - Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke Neurological Disorders Clinic - Durham
Ohio
- Cleveland Clinic - Cleveland
- Martha Morehouse Medical plaza - Columbus
Texas
- National Neuromuscular Research Institute - Austin
- Houston Methodist Neurological Institute - Houston
Arizona
- HonorHealth Neurology - Bob Bové Neuroscience Institute - Scottsdale
Illinois
- Northwestern Memorial Hospital - Chicago
Maryland
- University of California Irvine - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06558279
The ClinicalTrials.gov registry entry for NCT06558279 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis, Ocular appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod PH20 SC is the first listed.
NCT06558279 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06558279 about?
NCT06558279 is a clinical study titled "A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis". The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receiv...
What is the current status of trial NCT06558279?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2024-09-18. Estimated completion is 2027-12.
What conditions does trial NCT06558279 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Ocular.
What interventions are being tested in trial NCT06558279?
The interventions under investigation include: Efgartigimod PH20 SC (COMBINATION_PRODUCT), Placebo PH20 SC (OTHER).
Who is sponsoring clinical trial NCT06558279?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06558279 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis, Ocular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.